This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: CSPC Pharmaceutical Group (OtherCHJTF) and Wuxi Biologics (Cayman) (OtherWXIBF)

Tipranks - Tipranks - Sat May 30, 7:24PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CSPC Pharmaceutical Group (CHJTF) and Wuxi Biologics (Cayman) (WXIBF) with bullish sentiments.

Memorial Day Sale – Claim 70% Off TipRanks

CSPC Pharmaceutical Group (CHJTF)

Citi analyst John Yung maintained a Buy rating on CSPC Pharmaceutical Group on May 28 and set a price target of HK$11.50. The company’s shares closed last Friday at $1.05.

According to TipRanks.com, Yung is ranked #10723 out of 12284 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for CSPC Pharmaceutical Group with a $1.38 average price target, which is a 31.4% upside from current levels. In a report issued on May 28, CMB International Securities also maintained a Buy rating on the stock with a HK$13.05 price target.

See Insiders’ Hot Stocks on TipRanks >>

Wuxi Biologics (Cayman) (WXIBF)

In a report issued on May 28, Laurence Tam from Morgan Stanley maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$50.00. The company’s shares closed last Tuesday at $4.18.

According to TipRanks.com, Tam is ranked #10300 out of 12284 analysts.

Wuxi Biologics (Cayman) has an analyst consensus of Strong Buy, with a price target consensus of $5.79.

Read More on CHJTF:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).